Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Recruiting

Phase 2

Biomarker Selected TreatmentsUsing Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Sponsor:

SWOG Cancer Research Network

Code:

NCT06769126

Conditions

Extensive Stage Lung Small Cell Carcinoma

Lung Small Cell Carcinoma, A Subtype

Lung Small Cell Carcinoma, I Subtype

Lung Small Cell Carcinoma, N Subtype

Lung Small Cell Carcinoma, P Subtype

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Ceralasertib

Computed Tomography

Durvalumab

Etoposide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-10. This information was provided to ClinicalTrials.gov by SWOG Cancer Research Network on 2025-10-08.